Drug Profile
Research programme: RNAi therapeutics - Alnylam/Arrowhead Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Arrowhead Research Corporation
- Developer Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Hepatitis B; Liver disorders; Malaria; Metabolic disorders; Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in Germany (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in Portugal (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA (Parenteral)